Frank Dellanna, MD, and colleagues reviewed the journey of HX575 from development to approval in Europe, and describe a decade of clinical experience in patients with CKD, as the history and experience with this biosimilar provides an excellent example of a successful demonstration of biosimilarity.
Erythropoiesis-stimulating agents (ESAs), such as recombinant human erythropoietin, are commonly used to treat anemia in patients with chronic kidney disease (CKD). In May 2017, the FDA’s Oncologic Drugs Advisory Committee voted favorably following its review of the proposed epoetin alfa biosimilar, Epoetin Hospira.
In Europe, however, the first biosimilar (HX575, Binocrit) to originator epoetin alfa (Epogen, Procrit) was approved by the European Medicines Agency (EMA) in 2007. Thus, there are already 10 years of clinical experience of this biosimilar to epoetin alfa. Frank Dellanna, MD, and colleagues reviewed the journey of HX575 from development to approval in Europe, and describe a decade of clinical experience in patients with CKD, as the history and experience with this biosimilar provides an excellent example of a successful demonstration of biosimilarity.
The review, first presented in abstract form at the European Society for Medical Oncology’s 2017 meeting, appears in the December 2017 issue of Drug Design, Development and Therapy.
Like all biosimilar drugs in the research and development pipeline, HX575 (Sandoz GmbH, Kundl, Austria) proceeded through the many steps of an approval pathway in which it demonstrated biosimilarity through the totality of the evidence obtained in a comprehensive comparability exercise that involved extensive analytical characterization, nonclinical studies, and clinical studies—phase 1, phase 2, and phase 3 trials of the compound’s pharmacokinetics (PK), pharmacodynamics (PD), as well as confirmatory studies. Extensive clinical experience with HX575 over the last decade also confirms that it provides an effective treatment for anemia related to CKD, with a safety profile similar to those of other ESAs.
HX575 has generated more than 400,000 patient-years of experience worldwide in CKD and chemotherapy-induced anemia; with more widespread adoption, patient exposure and experience continues to increase.
The approval pathway for HX575 was as follows:
In conclusion, the successful approval and clinical use of more than 20 biosimilars in the European Union over the last decade affirms the integrity of the EMA’s biosimilar pathway, the researchers conclude.
Comparability exercises and extensive clinical experience over the last decade also confirm that HX575 provides an effective treatment for anemia related to CKD and its safety profile is similar to that of other ESAs. Growing clinical experience with EMA-approved biosimilars should offer additional reassurance to healthcare professionals and patients that these agents are as effective and well-tolerated as others in the therapeutic class.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.